Experienced in Generalized Pustular Psoriasis (GPP)

Dr. Craig Leonardi

Dermatology
Central Dermatology P.C.
1034 S Brentwood Blvd Ste 600, 
Saint Louis, MO 
Experienced in Generalized Pustular Psoriasis (GPP)
Central Dermatology P.C.
1034 S Brentwood Blvd Ste 600, 
Saint Louis, MO 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Craig Leonardi is a Dermatologist in Saint Louis, Missouri. Dr. Leonardi is rated as an Experienced provider by MediFind in the treatment of Generalized Pustular Psoriasis (GPP). His top areas of expertise are Psoriasis, Plaque Psoriasis, Atopic Dermatitis, and Contact Dermatitis.

His clinical research consists of co-authoring 112 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Generalized Pustular Psoriasis (GPP).

Specialties
Dermatology
Licenses
Dermatology in MO
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
HealthPartners
  • POS
  • PPO
Home State Health
  • EPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 1 Less Insurance Carrier -

Locations

Central Dermatology P.C.
1034 S Brentwood Blvd Ste 600, Saint Louis, MO 63117

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Completed
Publish Date: November 05, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Psoriasis
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Psoriasis
Enrollment Status: Completed
Publish Date: February 20, 2024
Intervention Type: Drug
Study Drug: LY3471851
Study Phase: Phase 1
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Atopic Dermatitis
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: February 20, 2024
Intervention Type: Drug
Study Drug: NKTR-358
Study Phase: Phase 1
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis.
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis.
Enrollment Status: Completed
Publish Date: May 24, 2023
Intervention Type: Biological, Other
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
Enrollment Status: Terminated
Publish Date: March 21, 2023
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis
An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: February 24, 2023
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Terminated
Publish Date: November 08, 2022
Intervention Type: Drug
Study Drug: Baricitnib
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 09, 2022
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Multiple-Dose, Randomized, Placebo-Controlled, Study of LY3462817 or LY3509754 in Patients With Psoriasis
A Multiple-Dose, Randomized, Placebo-Controlled, Study of LY3462817 or LY3509754 in Patients With Psoriasis
Enrollment Status: Terminated
Publish Date: March 15, 2022
Intervention Type: Drug
Study Drugs: LY3462817-IV, LY3462817-SV
Study Phase: Phase 1
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-2
Enrollment Status: Completed
Publish Date: March 30, 2021
Intervention Type: Drug
Study Phase: Phase 3
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: July 28, 2020
Intervention Type: Drug
Study Phase: Phase 4
A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo- Controlled Study of LY3074828 in Subjects With Moderate-to- Severe Plaque Psoriasis
A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo- Controlled Study of LY3074828 in Subjects With Moderate-to- Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: June 18, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 11 Less Clinical Trials

113 Total Publications

Current Treatments for Generalized Pustular Psoriasis: A Narrative Summary of a Systematic Literature Search.
Current Treatments for Generalized Pustular Psoriasis: A Narrative Summary of a Systematic Literature Search.
Journal: Dermatology and therapy
Published: May 31, 2024
Similar Doctors
Elite in Generalized Pustular Psoriasis (GPP)
Dr. Milan Anadkat
Dermatology
Elite in Generalized Pustular Psoriasis (GPP)
Dr. Milan Anadkat
Dermatology

Office

4901 Forest Park Ave Ste 502, 
Saint Louis, MO 
 (5.0 miles away)
314-273-3376
Languages Spoken:
English
See accepted insurances

Milan Anadkat is a Dermatologist in Saint Louis, Missouri. Dr. Anadkat is rated as a Distinguished provider by MediFind in the treatment of Generalized Pustular Psoriasis (GPP). His top areas of expertise are Pustular Psoriasis, Generalized Pustular Psoriasis (GPP), Pustules, and Hidradenitis Suppurativa.

Experienced in Generalized Pustular Psoriasis (GPP)
Dr. Connie Gibstine
Dermatology
Experienced in Generalized Pustular Psoriasis (GPP)
Dr. Connie Gibstine
Dermatology

St Louis Medical Clinic PC

3009 N Ballas Rd Ste 100B, 
Saint Louis, MO 
 (5.5 miles away)
314-994-0200
Languages Spoken:
English
See accepted insurances

Connie Gibstine is a Dermatologist in Saint Louis, Missouri. Dr. Gibstine is rated as a Distinguished provider by MediFind in the treatment of Generalized Pustular Psoriasis (GPP). Her top areas of expertise are Contact Dermatitis, Universal Acquired Melanosis, Liver Spots, and Actinic Keratosis.

Experienced in Generalized Pustular Psoriasis (GPP)
Dr. Sofia Chaudhry
Dermatology
Experienced in Generalized Pustular Psoriasis (GPP)
Dr. Sofia Chaudhry
Dermatology

SSM-Sluh Inc.

1225 S Grand Blvd, 
Saint Louis, MO 
 (5.8 miles away)
314-977-3400
Languages Spoken:
English
See accepted insurances

Sofia Chaudhry is a Dermatologist in Saint Louis, Missouri. Dr. Chaudhry is rated as an Experienced provider by MediFind in the treatment of Generalized Pustular Psoriasis (GPP). Her top areas of expertise are Stasis Dermatitis and Ulcers, Dermatomyositis, Psoriasis, and Granuloma Annulare.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Leonardi's expertise for a condition
ConditionClose
      View All 10 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile